KR20230008707A - 코로나바이러스 치료용 백신 조성물 - Google Patents

코로나바이러스 치료용 백신 조성물 Download PDF

Info

Publication number
KR20230008707A
KR20230008707A KR1020227037855A KR20227037855A KR20230008707A KR 20230008707 A KR20230008707 A KR 20230008707A KR 1020227037855 A KR1020227037855 A KR 1020227037855A KR 20227037855 A KR20227037855 A KR 20227037855A KR 20230008707 A KR20230008707 A KR 20230008707A
Authority
KR
South Korea
Prior art keywords
cov
seq
sars
polypeptide
spike
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227037855A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 이벤더 앤더슨
앤-캐서린 플루키거
Original Assignee
배리에이션 바이오테크놀로지스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 배리에이션 바이오테크놀로지스 아이엔씨. filed Critical 배리에이션 바이오테크놀로지스 아이엔씨.
Publication of KR20230008707A publication Critical patent/KR20230008707A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020227037855A 2020-03-30 2021-03-30 코로나바이러스 치료용 백신 조성물 Pending KR20230008707A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063002237P 2020-03-30 2020-03-30
US63/002,237 2020-03-30
US202063070150P 2020-08-25 2020-08-25
US63/070,150 2020-08-25
PCT/IB2021/000190 WO2021198769A1 (en) 2020-03-30 2021-03-30 Vaccine compositions for the treatment of coronavirus

Publications (1)

Publication Number Publication Date
KR20230008707A true KR20230008707A (ko) 2023-01-16

Family

ID=77927072

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037855A Pending KR20230008707A (ko) 2020-03-30 2021-03-30 코로나바이러스 치료용 백신 조성물

Country Status (10)

Country Link
US (1) US11253587B2 (https=)
EP (1) EP4126038A4 (https=)
JP (1) JP2023519837A (https=)
KR (1) KR20230008707A (https=)
AU (1) AU2021247583A1 (https=)
BR (1) BR112022019672A2 (https=)
CA (1) CA3142132C (https=)
IL (1) IL296578A (https=)
MX (1) MX2022012192A (https=)
WO (1) WO2021198769A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12558415B2 (en) * 2020-04-14 2026-02-24 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
WO2021234579A1 (en) * 2020-05-19 2021-11-25 National Research Council Of Canada Use of resistin as a trimerization partner for expression of trimeric proteins
WO2022051859A1 (en) * 2020-09-11 2022-03-17 Manuel Caruso Pseudotyped retroviral particles for inducing immunity against coronavirus infections
KR102744743B1 (ko) * 2021-10-25 2024-12-19 경희대학교 산학협력단 SARS-CoV-2의 스파이크 단백질 전부 또는 일부를 포함하는 바이러스 유사입자 및 이를 이용한 백신
EP4719470A1 (en) * 2023-06-02 2026-04-08 Variation Biotechnologies Inc. Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
WO2005118813A2 (en) * 2004-06-04 2005-12-15 Institut Pasteur Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
JP6046348B2 (ja) 2008-11-18 2016-12-14 タケダ ヴァクシーンズ， インコーポレイテッド Ｒｓｖｆｖｌｐならびにその製造および使用の方法
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
WO2011115583A1 (en) 2010-03-19 2011-09-22 National University Of Singapore A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens
WO2014128568A2 (en) * 2013-02-25 2014-08-28 Variation Biotechnologies, Inc. Compositions and methods for treatment of hepatitis c
MX2019000725A (es) * 2016-07-18 2019-07-04 Variation Biotechnologies Inc Composiciones de vacuna para tratamiento de virus zika.

Also Published As

Publication number Publication date
CA3142132C (en) 2024-06-04
IL296578A (en) 2022-11-01
AU2021247583A1 (en) 2022-11-03
WO2021198769A8 (en) 2021-12-23
CA3142132A1 (en) 2021-10-07
WO2021198769A9 (en) 2022-03-03
EP4126038A4 (en) 2024-04-17
JP2023519837A (ja) 2023-05-15
EP4126038A1 (en) 2023-02-08
US20210353741A1 (en) 2021-11-18
WO2021198769A1 (en) 2021-10-07
US11253587B2 (en) 2022-02-22
MX2022012192A (es) 2022-10-27
BR112022019672A2 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
US11911462B2 (en) Nucleic acid vaccine against the SARS-CoV-2 coronavirus
BE1023087B1 (fr) Antigenes du cytomegalovirus et leurs utilisations
RU2737530C1 (ru) Композиции и способы для лечения цитомегаловируса
JP2024503698A (ja) 変異型株ベースのコロナウイルスワクチン
KR20230008707A (ko) 코로나바이러스 치료용 백신 조성물
JP2023523423A (ja) ＳＡＲＳ－ＣｏＶ－２に対するワクチン及びその調製物
WO2024008014A1 (zh) 抗SARS-CoV-2或其突变体感染的药物组合物及其联合用药物
US20250026793A1 (en) Chimeric betacoronavirus spike polypeptides
CN115960180A (zh) 2019-nCoV S蛋白的突变体及其基因工程化的mRNA和疫苗组合物
US6673601B1 (en) Chimeric lyssavirus nucleic acids and polypeptides
US20220233682A1 (en) Vaccine compositions for the treatment of coronavirus
CN116549627A (zh) 基于腺病毒载体的广谱新冠疫苗及其应用
CN116457011A (zh) 用于治疗冠状病毒的疫苗组合物
KR102680105B1 (ko) 코로나19 바이러스 및 인플루엔자 h1n1 바이러스에 대한 바이러스 유사입자 및 이의 용도
US20260083836A1 (en) Modified coronavirus spike antigen protein and uses thereof
US20250312441A1 (en) Immunogenic compositions for herpes simplex virus proteins
EP4541806A1 (en) Modified coronavirus spike antigen protein and uses thereof
JP2026509062A (ja) Ｓａｒ－ｃｏｖ－２またはその変異型による感染に対するｍｒｎａワクチンおよび組換えタンパク質ワクチンならびにその適用
HK40095771A (zh) 预防突变株的新型冠状病毒mRNA疫苗
GB2624391A (en) Recombinant LSDV vectored bovine coronavirus antigen constructs
JP2024537847A (ja) ＣＯＶＩＤ１９ ｍＲＮＡワクチン
JP2024503482A (ja) 複製可能アデノウイルス４型ｓａｒｓ－ｃｏｖ－２ワクチンおよびそれらの使用
HK40066070A (zh) 一种mrna及包含其的新型冠状病毒mrna疫苗

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902